Transepithelial transport and enzymatic detoxification of gluten in gluten-sensitive rhesus macaques

PLoS ONE

Volumn 3, Issue 3, 2008, Pages

  Bethune, Michael T ^b   Ribka, Erin ^a   Khosla, Chaitan ^b,c   Sestak, Karol ^a,d  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Stanford University   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIADIN ANTIBODY; GLUTEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; RECOMBINANT ENDOPROTEASE B2; RECOMBINANT ENZYME; ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CELIAC DISEASE; CONTROLLED STUDY; DETOXIFICATION; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUTEN FREE DIET; IN VIVO STUDY; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; ISOTOPE LABELING; MASS SPECTROMETRY; NONHUMAN; PILOT STUDY; REMISSION; RHESUS MONKEY; ANIMAL; INTESTINE ABSORPTION; MACACA; METABOLISM; PERMEABILITY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALIA; MACACA; MACACA MULATTA;

ANIMALS; BIOLOGICAL TRANSPORT; ENZYMES; GLUTEN; INTESTINAL ABSORPTION; MACACA MULATTA; PERMEABILITY;

EID: 46649111178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001857     Document Type: Article

References (40)

1. Dicke WK, Weijers HA, Van De Kamer JH (1953) Coeliac disease. II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr 42: 34-42.
2. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, et al. (2002) Structural basis for gluten intolerance in celiac sprue. Science 297: 2275-2279.
3. Sollid LM (2002) Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2: 647-655.
4. Green PH, Jabri B (2006) Celiac disease. Annu Rev Med 57: 207-221.
5. See J, Murray JA (2006) Gluten-free diet: the medical and nutrition management of celiac disease. Nutr Clin Pract 21: 1-15.
6. Mayer M, Greco L, Troncone R, Auricchio S, Marsh MN (1991) Compliance of adolescents with coeliac disease with a gluten free diet. Gut 32: 881-885.
7. Ciacci C, Cirillo M, Cavallaro R, Mazzacca G (2002) long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage. Digestion 66: 178-185.
8. Pietzak MM (2005) Follow-up of patients with celiac disease: achieving compliance with treatment. Gastroenterology 128: S135-141.
9. Cornell HJ, Macrae FA, Melny J, Pizzey CJ, Cook F, et al. (2005) Enzyme therapy for management of coeliac disease. Scand J Gastroenterol 40: 1304-1312.
10. Shan L, Qiao SW, Arentz-Hansen H, Molberg O, Gray GM, et al. (2005) Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue. J Proteome Res 4: 1732-1741.
11. Hausch F, Shan L, Santiago NA, Gray GM, Khosla C (2002) Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 283: G996-G1003.
12. Fleckenstein B, Molberg O, Qiao SW, Schmid DG, von der Mulbe F, et al. (2002) Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process. J Biol Chem 277: 34109-34116.
13. Vader LW, de Ru A, van der Wal Y, Kooy YM, Benckhuijsen W, et al. (2002) Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med 195: 643-649.
14. Quarsten H, Molberg O, Fugger L, McAdam SN, Sollid LM (1999) HLA binding and T cell recognition of a tissue transglutaminase-modified gliadin epitope. Eur J Immunol 29: 2506-2514.
15. Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid L.M (2004) Structural basis for HIA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 101: 4175-4179.
16. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, et al. (1989) Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med 169: 345-350.
17. Spurkland A, Ingvarsson G, Falk ES, Knutsen I, Sollid LM, et al. (1997) Dermatitis herpetiformis and celiac disease are both primarily associated with the HLA-DQ (alpha 1*0501, beta 1*02) or the HLA-DQ (alpha 1*03, beta 1*0302) heterodimers. Tissue Antigens 49: 29-34.
18. Xia J, Sollid LM, Khosla C (2005) Equilibrium and kinetic analysis of the unusual binding behavior of a highly immunogenic gluten peptide to HLA-DQ2. Biochemistry 44: 4442-4449.
19. Qiao SW, Bergseng E, Melberg O, Xia J, Fleckenstein B, et al. (2004) Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion. J Immunol 173: 1757-1762.
20. Gass J, Vora H, Bethune MT, Gray GM, Khosla C (2006) Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat. J Pharmacol Exp Ther 318: 1178-1186.
21. Schulzke JD, Bentzel CJ, Schulzke I, Riecken EO, Fromm M (1998) Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. Pediatr Res 43: 435-441.
22. Bjarnason I, Peters TJ, Veall N (1983) A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labelled EDTA absorption test. Lancet 1: 323-325.
23. Bjarnason I, Peters TJ (1984) In vitro determination of small intestinal permeability: demonstration of a persistent defect in patients with coeliac disease. Gut 25: 145-150.
24. Bjarnasion I, Smethurst P, Levi AJ, Peters TJ (1985) Intestinal permeability to 51Cr-EDTA in rats with experimentally induced enteropathy. Gut 26: 579-585.
25. Bjarnason I, Marsh MN, Price A, Tevi AJ, Peters TJ (1985) Intestinal permeability in patients with coeliac disease and dermatitis herpetiformis. Gut 26: 1214-1219.
26. Teahon K, Somasundaram S, Smith T, Menzies I, Bjarnason I (1996) Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease. Gut 38: 864-869.
27. Bethune MT, Borda JT, Ribka E, Lin M-X, Phillippi-Falkenstein K, et al. (2008) A non-human primate model for gluten sensitivity. PLoS ONE in press.
28. Bethune MT, Strop P, Tang Y, Sollid LM, Khosla C (2006) Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease. Chem Biol 13: 637-647.
29. Siegel M, Bethune MT, Gass J, Ehren J, Xia J, et al. (2006) Rational design of combination enzyme therapy for celiac sprue. Chem Biol 13: 649-658.
30. Gass J, Bethune MT, Siegel M, Spencer A, Khosla C (2007) Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 133: 472-480.
31. Vora H, McIntire J, Kumar P, Deshpande M, Khosla C (2007) A scaleable manufacturing process for pro-EP-B2, a cysteine protease from barley indicated for celiac sprue. Biotechnol Bioeng 98: 177-185.
32. Jabri B, Kasarda DD, Green PH (2005) Innate and adaptive immunity: the yin and yang of celiac disease. Immunol Rev 206; 219-231.
33. Stepniak D, Koning F (2006) Enzymatic gluten detoxification: the proof of the pudding is in the eating! Trends Biotechnol 24: 433-434.
34. Cerf-Bensussan N, Matysiak-Budnik T, Cellier C, Heyman M (2007) Oral proteases: a new approach to managing coeliac disease. Gut 56: 157-160.
35. Piper JL, Gray GM, Khosla C (2002) High selectivity of human tissue transglutaminase for immumoactive gliadin peptides: implications for celiac sprue. Biochemistry 41: 386-393.
36. Hausch F, HaIttunen T, Maki M, Khosla C (2003) Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. Chem Biol 10: 225-231.
37. Pinkas DM, Strop P, Brunger AT, Khosla C (2007) Transglutaminase 2 undergoes a large conformational change upon activation. PLOS Biol 5: e327.
38. Esposito C, Paparo, F, Caputo I, Rossi M, Maglio M, et al. (2002) Anti-tissue transglutaminase antibodies from coeliac, patients inhibit transglutaminase activity both in vitro and in situ. Gut 51: 177-181.
39. Korponay-Szabo IR, Halttunen T, Szalai Z, Laurila. K, Kiraly R, et al. (2004) In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 53: 641-648.
40. Korponay-Szabo IR, Laurila K, Szondy Z, Halttunen T, Szalai Z, et al. (2003) Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues. Gut 52: 199-204.